SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

BRIEF-Prothena Announces Achievement Of $60 Mln From Roche For First Patient Dosed In Phase 2B Study Of Prasinezumab In Early Parkinson's Disease

05/10/2021 17:31
BRIEF-Prothena Announces Achievement Of $60 Mln From Roche For First Patient Dosed In Phase 2B Study Of Prasinezumab In Early Parkinson's Disease

- Prothena Corporation PLC PRTA.O:

  • PROTHENA ANNOUNCES ACHIEVEMENT OF $60 MILLION MILESTONE FROM ROCHE FOR FIRST PATIENT DOSED IN PHASE 2B STUDY OF PRASINEZUMAB IN EARLY PARKINSON’S DISEASE

Source text for Eikon: ID:nGNX5NrQlz

Further company coverage: PRTA.O


(([email protected];))